Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of dexrazoxane (Cardioxane) to prevent anthracycline-induced cardiotoxicity in breast cancer
2005-003217-32Phase 2Terminated
- Sponsor
- Azienda USL di Forlì
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dexrazoxane in breast cancer and Cardiotoxicity, sponsored by Azienda USL di Forlì. Started Apr 2006; status: terminated.
02
Drugs
dexrazoxane
03
Conditions
breast cancerCardiotoxicity
Beyond the preview
Go deeper on 2005-003217-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003217-32.